Amsterdam

• ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting
  2025-521884-12-00 5 2026-03-19 First line triple-negative breast cancer (TNBC)
• A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies Recruiting
  2024-516476-15-00 9 2026-03-04 Advanced gastrointestinal stromal tumor (GIST)
• TADalafil in early-stage Parkinson’s Disease (TAD-PD) Recruiting
  2025-521819-39-00 4 2026-03-02 Parkinson's disease
• A Study to assess the Safety, Tolerability and effect of RO7673396 when used alone as well as with other cancer medications in participants … Recruiting
  2024-519622-20-00 1 2026-02-27 Advanced Solid Tumors Harboring RAS Mutation(S)
• A Study of the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy. Recruiting
  2025-522553-19-00 10 2026-02-25 Symptomatic genetic and familial dilated cardiomyopathy.
• A clinical study of enlicitide in children with high cholesterol (MK-0616-029) Recruiting
  2024-519068-42-00 10 2026-02-12 ​Heterozygous Familial Hypercholesterolemia​ in pediatric patients
• A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E … Recruiting
  2024-518777-34-00 5 2026-02-11 B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
• A study to investigate the effect of adding bleximenib to standard-of-care treatment with intensive chemotherapy in patients with a specific … Recruiting
  2025-522767-15-00 5 2026-01-27 Acute Myeloid Leukemia
• Study for frail patients with newly diagnosed multiple myeloma treated with Daratumumab in combination with Teclistamab and Talquetamab. Recruiting
  2024-520433-76-00 4 2026-01-08 Newly Diagnosed Multiple Myeloma
• A study to assess efficacy and safety of empasiprubart versus IVIg in adults with CIDP ("emvigorate") Recruiting
  2024-520097-36-00 5 2026-01-07 Chronic inflammatory demyelinating polyneuropathy (CIDP)
• Study to investigate lifileucel regimen plus pembrolizumab compared with pembrolizumab alone in participants with untreated, advanced melano … Recruiting
  2022-503140-41-00 5 2025-12-19 Melanoma
• A clinical study to investigate if the investigational product, called LN -145 (also known as Tumor Infiltrating Lymphocytes) is safe and be … Recruiting
  2024-510778-26-00 4 2025-12-19 Metastatic Non-Small-Cell Lung Cancer
• HER2 molecular imaging with 89Zr-trastuzumab PET/CT as a predictive biomarker for antibody-drug conjugate sequencing in patients with advanc … Recruiting
  2024-516253-49-01 4 2025-12-12 advanced/metastatic HER2-positive breast carcinoma
• Adjuvant chemotherapy for prevention of recurrence in patients with detectable ctDNA after surgery in high-riskrectal cancer. Recruiting
  2024-517700-12-00 5 2025-12-10 Rectal cancer
• A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Partic … Recruiting
  2024-519157-10-00 3 2025-11-24 Systemic Lupus Erythematosus
• A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Study to Assess the Safety of ELGN-2112 in Populations … Recruiting
  2024-517102-29-00 5 2025-11-19 Intestinal Malabsorption
• Early treatment of irregular heartbeat (atrial fibrillation) to prevent a recurrent stroke Recruiting
  2025-521260-35-00 6 2025-11-07 acute ischemic stroke and atrial fibrillation (AF)
• The IPa-Gastric trial: Comparing Intraperitoneal Paclitaxel and Systemic Therapy versus Systemic Therapy alone in Gastric Cancer Patients wi … Recruiting
  2024-514879-17-00 5 2025-11-05 Gastric cancer
• EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial-1) Recruiting
  2025-521315-39-00 1 2025-11-05 Axial spondyloarthritis
• T3-4-Hypo trial Recruiting
  2024-513883-24-00 5 2025-11-02 Hypothyroidism Triiodothyronine Quality of Life Persistant complaints
• Long-term study to assess the safety and tolerability of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting
  2024-519423-24-00 5 2025-10-07 Major Depressive Disorder
• Open-label Study of ELA026 in Participants with sHLH (short title) Recruiting
  2025-520624-25-00 10 2025-09-19 Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
• Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 Recruiting
  2024-518144-20-00 7 2025-09-03 Primary Hyperoxaluria Type 1 (PH1)
• Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting
  2024-520107-12-00 5 2025-09-03 Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo

Showing 121–144 of 1,127 trials